What is Lifesci Capital’s Estimate for Savara Q2 Earnings?

Savara Inc. (NASDAQ:SVRA) – Investment analysts at Lifesci Capital boosted their Q2 2026 earnings estimates for shares of Savara in a research report issued to clients and investors on Sunday, March 15th. Lifesci Capital analyst F. Brisebois now expects that the company will post earnings of ($0.12) per share for the quarter, up from their prior estimate of ($0.13). The consensus estimate for Savara’s current full-year earnings is ($0.45) per share. Lifesci Capital also issued estimates for Savara’s FY2026 earnings at ($0.48) EPS.

SVRA has been the subject of several other reports. Oppenheimer set a $10.00 price target on Savara in a research report on Tuesday, December 23rd. Guggenheim reissued a “buy” rating on shares of Savara in a research note on Tuesday, December 23rd. William Blair set a $10.00 target price on Savara in a research report on Monday. HC Wainwright reissued a “buy” rating on shares of Savara in a research report on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Savara Stock Down 2.1%

Shares of NASDAQ SVRA opened at $5.04 on Wednesday. The firm has a market cap of $1.03 billion, a price-to-earnings ratio of -9.51 and a beta of 0.31. The company has a quick ratio of 7.65, a current ratio of 11.85 and a debt-to-equity ratio of 0.15. Savara has a 52-week low of $1.89 and a 52-week high of $7.01. The business’s 50 day moving average is $5.64 and its two-hundred day moving average is $4.99.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Friday, March 13th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01).

Institutional Investors Weigh In On Savara

Several large investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd increased its holdings in Savara by 1,887.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 39,649 shares of the company’s stock worth $239,000 after purchasing an additional 37,654 shares during the period. Seven Fleet Capital Management LP purchased a new position in shares of Savara in the 4th quarter valued at about $378,000. Virtu Financial LLC acquired a new position in shares of Savara during the fourth quarter worth about $396,000. Invesco Ltd. grew its position in shares of Savara by 302.1% during the fourth quarter. Invesco Ltd. now owns 688,595 shares of the company’s stock worth $4,152,000 after buying an additional 517,329 shares in the last quarter. Finally, KVP Capital Advisors LP purchased a new stake in shares of Savara during the fourth quarter worth approximately $3,650,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Key Savara News

Here are the key news stories impacting Savara this week:

• Positive Sentiment: Lifesci Capital nudged up near‑term forecasts — Q2 2026 EPS raised to ($0.12) from ($0.13) and FY2026 to ($0.48) from ($0.49). These marginal improvements signal slightly better expected near‑term performance. MarketBeat Savara Coverage
• Neutral Sentiment: HC Wainwright released detailed quarterly/near‑term model assumptions (Q1–Q4 2026 EPS estimates around ($0.13)–($0.09)) and reiterated a Buy rating — providing a full modeling framework investors can use but not a clear directional catalyst. MarketBeat Savara Coverage
• Negative Sentiment: HC Wainwright lowered FY2026 estimates (to ($0.49) from ($0.39)) and materially cut FY2027/FY2028 projections (FY2027 now ($0.28) vs prior ($0.16); FY2028 cut to $0.02 from $0.13), indicating the firm now models later profitability and/or slower commercial/clinical ramp than previously expected. MarketBeat Savara Coverage
• Negative Sentiment: HC Wainwright also trimmed longer‑term upside (FY2029 and FY2030 EPS reduced from prior forecasts), which lowers forward conviction and could pressure valuation until clearer clinical/commercial milestones arrive. MarketBeat Savara Coverage

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.